

Development of a reverse genetics system for snakehead vesiculovirus (SHVV)



Shuangshuang Feng^a, Jianguo Su^a, Li Lin^{b,*}, Jiagang Tu^{a,c,**}

^a Department of Aquatic Animal Medicine, College of Fisheries, Huazhong Agricultural University, Wuhan, Hubei, 430070, China

^b Guangdong Provincial Water Environment and Aquatic Products Security Engineering Technology Research Center; Guangzhou Key Laboratory of Aquatic Animal Diseases and Waterfowl Breeding; Guangdong Provincial Key Laboratory of Waterfowl Healthy Breeding, College of Animal Sciences and Technology, Zhongkai University of Agriculture and Engineering, Guangzhou, Guangdong 510225, China

^c Hubei Engineering Technology Research Center for Aquatic Animal Diseases Control and Prevention, Wuhan, Hubei, 430070, China

ARTICLE INFO

Keywords:

Snakehead vesiculovirus
Reverse genetics
EGFP
Vaccine

ABSTRACT

Snakehead vesiculovirus (SHVV) is a new rhabdovirus isolated from diseased hybrid snakehead fish (*Channa maculate* ♀ x *Channa argus* ♂) and has caused serious economic losses in snakehead fish culture in China. To better understand the pathogenicity of SHVV, we developed a reverse genetics system for SHVV by using human and fish cells. In detail, human 293T cells were co-transfected with four plasmids encoding the full-length SHVV antigenomic RNA or the supporting proteins including nucleoprotein (N), phosphoprotein (P), and large polymerase (L), followed by the cultivation in Channel catfish ovary (CCO) cells. We also rescued a recombinant SHVV expressing enhanced green fluorescent protein (EGFP), which was inserted into the 3' non-coding region (NCR) of the glycoprotein (G) gene of SHVV. Our study provides a potential tool for unveiling the pathogenicity of SHVV and a template for the rescue of other fish viruses by using both human 293T and fish cells.

1. Introduction

In 2014, a serious disease with high mortality outbreak in cultured hybrid snakehead fish (*Channa maculate* ♀ x *Channa argus* ♂) in Guangdong province of China. From the diseased hybrid snakehead fish, we isolated a virus that was further identified as a new rhabdovirus called snakehead vesiculovirus (SHVV) via genome sequencing (Liu et al., 2015). The genome of SHVV consists of a non-segmented negative-sense RNA, which encodes five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and RNA-dependent RNA polymerase or called large polymerase (L). Since the first outbreaks of SHVV, it has caused serious economic losses in snakehead fish culture in China. However, little is known about the pathogenicity of SHVV and the available vaccine against SHVV is currently lacking.

The availability of reverse genetics systems have expanded the range of studies that can be conducted with rhabdoviruses (Fang et al., 2015; Nakagawa et al., 2017; Okada et al., 2016; Schnell et al., 1994; Stanifer et al., 2011). The most extensively studied rhabdoviruses are rabies virus (RV) and vesicular stomatitis virus (VSV), which belong to

Lyssavirus or *Vesiculovirus* genus, respectively. Similar to the mammalian rhabdoviruses RV and VSV, reverse genetics has also been developed for fish rhabdoviruses that belong to *Novirhabdovirus* genus, including infectious hematopoietic necrosis virus (IHNV) and viral haemorrhagic septicaemia virus (VHSV) (Ammayappan et al., 2011; Ammayappan et al., 2010). However, no reverse genetics has been established for fish rhabdoviruses that belong to *Sprivirus* or *Perhabdovirus* genus, such as spring viraemia of carp virus (SVCV), Siniperca chuatsi rhabdovirus (SCRV), *Monopterus albus* rhabdovirus (MARV), and SHVV. Thereby, it is necessary to generate reverse genetics system for fish rhabdovirus SHVV, which will help understanding the virus pathogenicity.

In this study, we developed a reverse genetics system for SHVV. To our knowledge, it is the first time to rescue fish viruses using both human and fish cells. We also generated a recombinant SHVV expressing a fluorescent reporter protein EGFP by inserting EGFP gene into the viral genome. This study builds an appropriate tool that will be useful for future studies on understanding the molecular mechanism of SHVV pathogenicity.

* Corresponding author.

** Corresponding author at: Department of Aquatic Animal Medicine, College of Fisheries, Huazhong Agricultural University, Wuhan, Hubei 430070, China.
E-mail addresses: linli@zhku.edu.cn (L. Lin), tujagang@mail.hzau.edu.cn (J. Tu).

<https://doi.org/10.1016/j.virol.2018.10.002>

Received 17 July 2018; Received in revised form 24 August 2018; Accepted 3 October 2018

Available online 15 October 2018

0042-6822/ © 2018 Elsevier Inc. All rights reserved.

2. Results and discussion

Reverse genetics system allows for precise manipulation of viral genomes to study viral pathogenicity, to screen antiviral compounds, and to develop vaccines. Since the first recovery of rabies virus from cDNA in 1994 (Schnell et al., 1994), the reverse genetics has been established for rhabdoviruses by co-transfecting the supporting plasmids encoding N, P, and L proteins together with a plasmid encoding the full-length viral antigenome into permissive cells (Biacchesi, 2011). Initially, all the plasmids used in the reverse genetics system were under control of T7 polymerase promoter. Thereby, the permissive cells were either infected with a recombinant vaccinia virus to provide T7 RNA polymerase or constitutively expressing T7 RNA polymerase (Alonso et al., 2004; Fuerst et al., 1986). Later, the cDNA encoding N, P, and L proteins and the viral antigenome were cloned into plasmids under control of Cytomegalovirus (CMV) promoter, which was driven by cellular RNA polymerase II (Ammayappan et al., 2011; Ammayappan et al., 2010; Huang et al., 2010). The aim of this study is to establish the reverse genetics system of SHVV by using plasmids under control of CMV promoter. The whole genome sequencing of SHVV has been previously performed (Liu et al., 2015). Using this genome sequence (KP876483.1), the entire SHVV antigenome flanked with the self-cleaving hammerhead ribozyme (HamRz) and hepatitis delta virus ribozyme (HdvRz) sequences at its 5'- and 3'-end was cloned step by step into vector pCDNA3.1 (+) (Fig. 1A). Ribozyme sequences were used to guarantee the expression of an antigenome RNA having precise 5'- and

3'-end without any additional nucleotides (Biacchesi, 2011). The constructed plasmid pCDNA-SHVV was about 17 Kb in length and confirmed by restriction digestion (Fig. 1B). In addition, for the rescue of SHVV, we also constructed three supporting plasmids pCDNA-N, pCDNA-P, and pCDNA-L expressing N, P, or L protein of SHVV, respectively (data not shown).

To rescue the recombinant SHVV (rSHVV), we initially tried several fish cells including Channel catfish ovary (CCO) cells, striped snakehead (SSN-1) cells, and fathhead monnow (FHM) cells using different transfection reagents and electrotransfection. Probably because of the low transfection efficiency of fish cells, the rescue of SHVV was not successful. Human 293T cells have been extensively used for the rescue of influenza viruses due to its high transfection efficiency (Crescenzo-Chaigne and van der Werf, 2007; Tu et al., 2011; Zhao et al., 2014). In this study, we tried to rescue fish rhabdovirus SHVV using human 293T cells based on its high transfection efficiency and fish CCO cells based on its high efficiency for SHVV replication. 293T cells were transfected with the plasmid pCDNA-SHVV and supporting plasmids pCDNA-N, pCDNA-P, pCDNA-L. For the negative control, 293T cells were only transfected with plasmid pCDNA-SHVV. The cytopathic effect (CPE) was observed daily for 3 days. As shown in Fig. 2A, CPE that cells became rounded and floated could be observed in partial 293T cells transfected with the full-length plasmid and supporting plasmids at 3 days post of transfection (Fig. 2A right), but not in the negative control (Fig. 2A left). To determine whether the CPE was caused by the generated virus, we detected viral G mRNA using RT-PCR. The results




Fig. 1. Construction of the plasmids used for the rescue of SHVV. (A) Schematic representation of the plasmid pCDNA-SHVV encoding the full-length SHVV antigenome and the supporting plasmids pCDNA-N, pCDNA-P, pCDNA-L. (B) Confirmation of the constructed plasmid pCDNA-SHVV by restriction digestion with enzyme *SalI*. M: DNA marker; Lane 1: the plasmid of pCDNA-SHVV; Lane 2: restriction digestion of pCDNA-SHVV with enzyme *SalI*, the predicted products are 9760, 5069, and 2187 bp.




Fig. 2. The rescue of SHVV from cDNA. (A) 293T cells in 6-well plates were transfected with plasmids pCDNA-SHVV, pCDNA-N, pCDNA-P, and pCDNA-L (right) or only pCDNA-SHVV as control (left) for 3 days. (B) SHVV G gene was detected by RT-PCR for the cells collected from (A), M: DNA marker; lane 1: CCO cells without SHVV infection was used as negative control; lane 2: sample from the left of (A); lane 3: sample from the right of (A); lane 4: CCO cells with SHVV infection was used as positive control. (C) The supernatants collected from (A) were incubated with fresh CCO cells and the CPE was observed daily. (D) The SHVV G protein was detected by western blot for the cells collected from (C), M: protein marker; lane 1: CCO cells without SHVV infection was used as negative control; lane 2: sample from the left of (C); lane 3: sample from the right of (C); lane 4: CCO cells with SHVV infection was used as positive control.

SHVV infection was used as negative control; lane 2: sample from the left of (C); lane 3: sample from the right of (C); lane 4: CCO cells with SHVV infection was used as positive control.




Fig. 5. Comparison of the growth ability of rSHVV and rSHVV-EGFP. (A) Comparison of the rescue efficiency of rSHVV and rSHVV-EGFP by measuring the viral titers in the supernatants of the samples from Fig. 2C (right) and Fig. 4C (right) using TCID_{50} . (B) CCO cells were infected with 1 MOI of rSHVV or rSHVV-EGFP, at 3, 6, 12, and 24 h poi, the cells and supernatants were collected for viral detection. The viral G mRNA was measured using qRT-PCR. β -actin was used as the internal control. (C) The SHVV titers in the supernatants from (B) were measured using TCID_{50} . (D) CCO cells were transfected with 2 μg of pCDNA3.1 or pCDNA-G for 24 h, followed by the incubation with the supernatants from Fig. 4B (right). The viral N, G, and EGFP proteins were detected by western blot, β -actin was used as the internal control. The integrated optical densities of the protein bands were measured using Image-Pro Plus 6.0. The value of viral N, G and EGFP protein bands were normalized to that of β -actin. The value of the viral N, G and EGFP protein bands in pCDNA3.1 transfected cells were set as 100, respectively. (E) The SHVV titers in the supernatants from (D) were measured using TCID_{50} . All the data are performed in triplicate (mean \pm SD). The * and ** respectively indicate statistically significant differences (*, $p < 0.05$; **, $p < 0.01$).

growth kinetics of rSHVV and rSHVV-EGFP. CCO cells were infected with 1MOI of rSHVV or rSHVV-EGFP, the cells and supernatants were collected at 3, 6, 12 and 24 h poi for viral detection via qRT-PCR or TCID_{50} . The results showed that rSHVV-EGFP grew slower than rSHVV (Figs. 5B and 5C). At 24 h poi, the viral titer of rSHVV-EGFP was about 5 log less than that of rSHVV (Fig. 5C). These data demonstrated that insertion of a foreigner gene EGFP into the 3'NCR of viral G gene impaired the growth ability of rSHVV-EGFP.

It was hypothesized that the insertion of EGFP into the 3'NCR of viral G gene probably affected the expression of viral G protein, thus impaired the virus growth. To determine whether additionally providing G protein in cells will improve the growth ability of rSHVV-EGFP, CCO cells were transfected with pCDNA3.1 or pCDNA-G, followed by the infection of rSHVV-EGFP. As shown in Figs. 5D and 5E, additionally providing G protein in cells significantly increased expression of EGFP and viral proteins. Moreover, the viral titer was also increased by providing additional G protein in cells although it was still lower than that of rSHVV (Figs. 5A and 5E). These data suggested that insertion of EGFP into the 3'NCR of G gene impaired the growth of SHVV via affecting G protein expression, while additionally providing G protein could improve its growth ability.

3. Conclusions

In this study, we describe a highly efficient reverse genetics system to generate fish rhabdovirus SHVV using human 293T and fish CCO cells. This human-fish cell combined way might also be used for the rescue of other fish viruses. We also report the successful rescue of a recombinant virus rSHVV-EGFP expressing a fluorescent report protein

EGFP. However, the insertion of EGFP into the 3'NCR of SHVV G gene suppresses the rescue efficiency and growth ability of the rSHVV-EGFP. Further studies are needed to generate more suitable recombinant virus rSHVV-EGFP for screening of antiviral drugs.

4. Materials and methods

4.1. Cells and viruses

Human 293T cells were cultured at 37 °C with 5% CO_2 in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, New Zealand) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, New Zealand), penicillin (100 $\mu\text{g}/\text{ml}$), and streptomycin (100 $\mu\text{g}/\text{ml}$). CCO cells were cultured at 25 °C in minimum essential medium (MEM) (Gibco, New Zealand) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, New Zealand), penicillin (100 $\mu\text{g}/\text{ml}$), and streptomycin (100 $\mu\text{g}/\text{ml}$). SHVV was isolated from diseased hybrid snakehead fish and stored at -80 °C.

4.2. Antibodies

The antibody against G and N proteins of SHVV was produced by immunizing rabbits with G or N proteins expressed in *E. coli*. The antibody against β -actin and EGFP was purchased from Bioss Biotechnology Co., LTD. (Beijing, China). The secondary anti-rabbit or anti-mouse IgG antibody was purchased from Gene Co., LTD. (Shanghai, China).

Table 1
Primers used in this study.

Application	Primer	Sequence (5'–3')	
Full-length plasmid	8K-FW	CGGCTAGCGTTTTGGAAGGTGGTCTAC	
	Hdv-BW	GCTCTAGATGGCTCTCCCTTAGCCATCCGAGTGGACGTGCGTCTCTCGGATGCCAGG TCGGACCGGAGGAGGTGGAGATGCCATGCCGCCACGAGAAAAACAACAGTCTCTGATTAGC	
	4K-FW	CGGCTAGCAAACACACAGTATCTCTGCG	
	8K-BW	CGGAATTCGGCCAAAAATCTTGGAAATA	
	Ham-FW	TCACTATAGGGAGACCAAGCTGGACTGATGAGTCCGTGAGGACGAACTATAGGAAAGGAATTCCT ATAGTCACGAGAAAAAAGAAACCAA	
	4K-BW	ACCCTTGATAGGTAGCCTTGGAAAGCTTGC	
	qRT-PCR	SHVV-G-FW	ACACCATACATGCCAGAGGC
		SHVV-G-BW	GCCTCGCTGGGTATCCAAAT
		β-actin-FW	CACTGTGCCATCTACGAG
		β-actin-BW	CCATCTCTGCTCGAAGTC
PCDNA-N-FW		GGGGTACCAACAGATATCATATCTGAAT	
Supporting plasmids	PCDNA-N-BW	GCTCTAGATTTTTTTCATATCCCATCAC	
	PCDNA-P-FW	GGGGTACCAACAGATATCATGGCAAAAC	
	PCDNA-P-BW	GCTCTAGATTTTTTTCATATCTCTCTGA	
	PCDNA-L-FW	GGGGTACCATGGATTATCTCAGGAATA	
	PCDNA-L-BW	GCCGGGCCCTTATTCGTCCACGCGCTT	
Mutant plasmids	Sse8387I-FW	CTTAAATGGGTGATTGCTCTGCAGGATGATATATTG	
	Sse8387I-BW	CCTGCAGGACAATCACCCATTTAAGAGCTTGTAATAG	
	EGFP-Sse8387I-FW	GCTCTAAATGGGTGATTGCTCTGCAGGATGAGCAAGGGCGAGGA	
	EGFP-Sse8387I-BW	TCATCGAGACAATATATCATCTGCATTACTTGTACAGCTCGTCCATG	

4.3. Plasmids

The plasmid pCDNA-SHVV containing the full-length of SHVV antigenome was constructed as shown in Fig. 1A using primers listed in Table 1. In step 1, *NheI* and *XbaI* were used to clone ~8–11 K of SHVV antigenome with HdvRz at its 3'-end into pCDNA3.1. In step 2 and 3, the ~4–8 K and ~1–4 K of SHVV antigenome with HamRz at its 5'-end were cloned into pCDNA-8–11K by *NheI* or *HindIII* respectively using pEASY-Uni Seamless Cloning and Assembly Kit (TransGen, China). The supporting plasmids pCDNA-N, pCDNA-P, and pCDNA-L were constructed by amplifying the ORF of corresponding genes into vector pCDNA3.1 using primers listed in Table 1. The mutant plasmid pCDNA-SHVV-Sse8387I was constructed by PCR-mediated insertion of Sse8387 I enzyme site into the 3'NCR of G gene in the plasmid pCDNA-SHVV using primers listed in Table 1. The plasmid pCDNA-SHVV-EGFP was constructed by the insertion of EGFP into the Sse8387 I site of the plasmid pCDNA-SHVV-Sse8387I using primers listed in Table 1.

4.4. Reverse genetics

Human 293T cells were co-transfected with the supporting plasmids pCDNA-N (1.6 μg), pCDNA-P (1.6 μg), and pCDNA-L (0.8 μg) together with the full-length plasmid pCDNA-SHVV (3.2 μg) or the mutant plasmid pCDNA-SHVV-EGFP (3.2 μg) using TransIntro™ EL Transfection Reagent (TransGen Biotech, China). At 6 h post of transfection, the medium was replaced by 1 ml of DMEM with 10% FBS and continued incubation at at 37 °C with 5% CO₂ for 3 days. The cells were freeze-thawed for three times and then centrifuged at 10,000 × g for 5 min. The supernatant was subsequently incubated with fresh CCO cells and the CPE was observed daily.

4.5. Virus infection and titration

CCO cells were incubated with wtSHVV, rSHVV, or rSHVV-EGFP at a MOI of 1. After 2-h adsorption at 25 °C, the inoculum was removed and the cells were washed twice with PBS followed by adding MEM with 5% FBS. At different time point poi, the supernatants were collected for virus titration by TCID₅₀, and the cells were harvested for the detection of viral proteins by western blot or viral mRNAs by qRT-PCR with primers listed in Table 1.

4.6. Quantitative RT-PCR

Total RNAs were extracted from cells with TRIzol reagent (Invitrogen) according to manufacturer's instructions as described previously (Zhang et al., 2017a; Zhang et al., 2017b). For the detection of SHVV G mRNA, 1 μg of RNA was mixed with 1 μl Oligo (dT), 4 μl 4 × gDNA wiper Mix, and RNase free H₂O to a total volume of 16 μl. After incubated at 42 °C for 2 min, 4 μl 5x select qRT supermix II was added and incubated at 50 °C for 15 min and 85 °C for 2 min. The PCR reactions were conducted in 20 μl volumes containing 10 μl mix, 1 μl cDNA template, 1 μl of SHVV-G forward primer, 1 μl of SHVV-G backward primer, and 7 μl ddH₂O with the following cycling conditions: 95 °C for 5 min, 30 cycles at 94 °C for 1 min, 57 °C for 30 s, and 72 °C for 90 s, and ended with a 72 °C at 7 min. The quantitative PCR reactions were conducted in 20 μl volumes containing 10 μl AceQ qPCR SYBR Green Master mix, 1 μl cDNA template, 0.4 μl of forward primer, 0.4 μl of backward primer, and 8.2 μl ddH₂O with the following cycling conditions: 95 °C for 5 min, 45 cycles at 95 °C for 10 s, 60 °C for 10 s, and 72 °C for 15 s, and ended with a 95 °C at 5 °C/s calective velocity to make the melt curve. Data were normalized to the level of β-actin in each sample using the 2^{-ΔΔCt} method (Livak and Schmittgen, 2001).

4.7. Western blot

The extracted proteins from CCO cells were extracted by cell lysis buffer, separated by SDS-PAGE gel and transferred onto a nitrocellulose membrane (Biosharp, China). Membranes were blocked with 5% skim milk in tris-buffered saline with tween 20 (TBST) at 4 °C overnight, followed by incubation with the anti-G (1:1000), anti-N (1:1000), anti-EGFP (1:3000), or anti-β-actin (1:1000) antibodies for 2 h at room temperature. The membranes were then washed three times by TBST and incubated with IRDye 800CW conjugated anti-rabbit antibody (for G and N proteins, 1:10,000) or anti-mouse antibody (for EGFP protein, 1:10,000) for 1 h at room temperature. The signal intensity was then determined using Odyssey CLx (LI-COR, USA).

4.8. Statistical analysis

All statistical analyses were performed using Graphpad Prism 5.0 (GraphPad Software, CA). The statistical significance of the data was

determined by Student *t*-test, and $P < 0.05$ was considered statistically significant.

Acknowledgments

This work was jointly supported by National Natural Science Foundation of China (31602195, 31572657), the Fundamental Research Funds for the Central Universities (52209–818090, 2662018QD017), Fund from Wuhan Science and Technology Bureau (2016020101010089), and "Innovation and Strong Universities" special fund from the Department of Education of Guangdong Province (KA170500G).

References

- Albarino, C.G., Uebelhoer, L.S., Vincent, J.P., Khristova, M.L., Chakrabarti, A.K., McElroy, A., Nichol, S.T., Towner, J.S., 2013. Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. *Virology* 446, 230–237.
- Alonso, M., Kim, C.H., Johnson, M.C., Pressley, M., Leong, J.A., 2004. The NV gene of snakehead rhabdovirus (SHRV) is not required for pathogenesis, and a heterologous glycoprotein can be incorporated into the SHRV envelope. *J. Virol.* 78, 5875–5882.
- Ammayappan, A., Kurath, G., Thompson, T.M., Vakharia, V.N., 2011. A reverse genetics system for the Great lakes strain of viral hemorrhagic septicemia virus: the NV gene is required for pathogenicity. *Mar. Biotechnol.* 13, 672–683.
- Ammayappan, A., Lapatra, S.E., Vakharia, V.N., 2010. A vaccinia-virus-free reverse genetics system for infectious hematopoietic necrosis virus. *J. Virol. Methods* 167, 132–139.
- Biacchesi, S., 2011. The reverse genetics applied to fish RNA viruses. *Vet. Res.* 42, 12.
- Crescenzo-Chaigne, B., van der Werf, S., 2007. Rescue of influenza C virus from recombinant DNA. *J. Virol.* 81, 11282–11289.
- Fang, X., Qi, B., Ma, Y., Zhou, X., Zhang, S., Sun, T., 2015. Assessment of a novel recombinant vesicular stomatitis virus with triple mutations in its matrix protein as a vaccine for pigs. *Vaccine* 33, 6268–6276.
- Fuerst, T.R., Niles, E.G., Studier, F.W., Moss, B., 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus That synthesizes bacteriophage-T7 RNA-polymerase. *Proc. Natl. Acad. Sci. USA* 83, 8122–8126.
- Huang, Y., Tang, Q., Nadin-Davis, S.A., Zhang, S., Hooper, C.D., Ming, P., Du, J., Tao, X., Hu, R., Liang, G., 2010. Development of a reverse genetics system for a human rabies virus vaccine strain employed in China. *Virus Res.* 149, 28–35.
- Liu, X.D., Wen, Y., Hu, X.Q., Wang, W.W., Liang, X.F., Li, J., Vakharia, V., Lin, L., 2015. Breaking the host range: mandarin fish is susceptible to a vesiculovirus derived from snakehead fish. *J. General. Virol.* 96, 775–781.
- Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. *Methods* 25, 402–408.
- Lo, M.K., Nichol, S.T., Spiropoulou, C.F., 2014. Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. *Antivir. Res.* 106, 53–60.
- Nakagawa, K., Kobayashi, Y., Ito, N., Suzuki, Y., Okada, K., Makino, M., Goto, H., Takahashi, T., Sugiyama, M., 2017. Molecular function analysis of rabies virus RNA polymerase L protein by using an L gene-deficient virus. *J. Virol.* 91.
- Okada, K., Ito, N., Yamaoka, S., Masatani, T., Ebihara, H., Goto, H., Nakagawa, K., Mitake, H., Okadera, K., Sugiyama, M., 2016. Roles of the rabies virus phosphoprotein isoforms in pathogenesis. *J. Virol.* 90, 8226–8237.
- Schnell, M.J., Mebatsion, T., Conzelmann, K.K., 1994. Infectious rabies viruses from cloned cDNA. *EMBO J.* 13, 4195–4203.
- Schudt, G., Kolesnikova, L., Dolnik, O., Sodeik, B., Becker, S., 2013. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances. *Proc. Natl. Acad. Sci. USA* 110, 14402–14407.
- Stanifer, M.L., Cureton, D.K., Whelan, S.P., 2011. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. *J. Virol.* 85, 8105–8115.
- Tu, J., Guo, J., Zhang, A., Zhang, W., Zhao, Z., Zhou, H., Liu, C., Chen, H., Jin, M., 2011. Effects of the C-terminal truncation in NS1 protein of the 2009 pandemic H1N1 influenza virus on host gene expression. *PLoS One* 6, e26175.
- Uebelhoer, L.S., Albarino, C.G., McMullan, L.K., Chakrabarti, A.K., Vincent, J.P., Nichol, S.T., Towner, J.S., 2014. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. *Antivir. Res.* 106, 86–94.
- Zhang, C., Feng, S., Zhang, W., Chen, N., Hegazy, A.M., Chen, W., Liu, X., Zhao, L., Li, J., Lin, L., Tu, J., 2017a. MicroRNA mir-214 inhibits Snakehead Vesiculovirus replication by promoting IFN-alpha expression via targeting host adenosine 5'-Monophosphate-activated protein kinase. *Front. Immunol.* 8, 1775.
- Zhang, C., Yi, L., Feng, S., Liu, X., Su, J., Lin, L., Tu, J., 2017b. MicroRNA mir-214 inhibits snakehead vesiculovirus replication by targeting the coding regions of viral N and P. *J. Gen. Virol.* 98, 1611–1619.
- Zhao, Z., Yi, C., Zhao, L., Wang, S., Zhou, L., Hu, Y., Zou, W., Chen, H., Jin, M., 2014. PB2-588I enhances 2009 H1N1 pandemic influenza virus virulence by increasing viral replication and exacerbating PB2 inhibition of beta interferon expression. *J. Virol.* 88, 2260–2267.